For the Inventor, By the Inventor

Enter assignee name

Boulogne-Billancourt, France

Pierre Fabre Medicament

USPTO Granted Patents = 269

% Expired Patents = 36.8

CIPO Patents = 22

EPO Patents = 134

Trademarks = 7

Forward Citations = 1,191

Loading Chart...

Loading Chart...

325 inventors (with patents filed for the assignee):

Liliane Goetsch (43 out of 45 patents)

Michel Perez (24 out of 24 patents)

Bernard Vacher (22 out of 22 patents)

4. Thierry Imbert (20 out of 22 patents)

5. Jean-François Haeuw (18 out of 18 patents)

6. Nathalie Corvaia (14 out of 15 patents)

7. Yves Guminski (13 out of 14 patents)

8. Wouter Koek (13 out of 13 patents)

9. Marie Lamothe (12 out of 12 patents)

10. Alexandra Jouhanneaud (12 out of 12 patents)

11. Elisabeth Dupont-Passelaigue (11 out of 11 patents)

12. Dennis C Bigg (11 out of 23 patents)

13. Charlotte Beau-Larvor (10 out of 11 patents)

14. Anna Kruczynski (10 out of 10 patents)

15. Joël Bougaret (10 out of 12 patents)

Core Competencies:

Antibody-Drug Conjugate

RAF Inhibitor

Immunocytokines

Cancer Metastasis

Movement Disorders

C-Met Antagonist

Trilobine Derivatives

Dopamine D3 Receptor

DNA Methyltransferase Inhibitors

Prostate Pathologies

Antigen Binding Protein

Therapeutic Use

269 patents: Sort by Forward Citations

1. 12692248 - Solid state forms of (S)-N-(3-(2-(((R)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof (2026-07-28),

2. 12679896 - ANTI-cMET ANTIBODY (2026-07-14),

3. 12569496 - Treatment of cancer with a RAF inhibitor (2026-03-10),

4. 12472169 - Method for treating movement disorders with befiradol (2025-11-18),

5. 12312336 - Inhibitors of RAF kinases (2025-05-27),

6. 12209129 - Anti-Met fab-Fc for the treatment of a tumor and/or metastasis (2025-01-28),

7. 12011485 - Sulfomaleimide-based linkers and corresponding conjugates (2024-06-18),

8. 11918656 - Antibody-drug-conjugate and its use for the treatment of cancer (2024-03-05),

9. 11873339 - Anti-C10orf54 antibodies and uses thereof (2024-01-16),

10. 11673931 - Immunocytokines for the treatment of cancer (2023-06-13),

11. 11661457 - IGF-1R antibody-drug-conjugate and its use for the treatment of cancer (2023-05-30),

12. 11517625 - Antibody-drug-conjugate and its use for the treatment of cancer (2022-12-06),

13. 11365259 - IGF-1R antibody and its use as addressing vehicle for the treatment of cancer (2022-06-21),

14. 11340233 - Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples (2022-05-24),

15. 11311591 - Use of copaifera oleoresin in pathologies of the prostate (2022-04-26),

Company Overview

Pierre Fabre Medicament, based in Boulogne-Billancourt, France, is a prominent player in the field of cancer treatment. The company specializes in innovative therapies, focusing on advanced technologies such as antibody-drug conjugates and RAF inhibitors. Its research extends to immunocytokines and strategies to combat cancer metastasis, as well as addressing movement disorders through targeted treatments. With a commitment to enhancing patient outcomes, Pierre Fabre Medicament is dedicated to pioneering solutions in oncology and related therapeutic areas.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

269 Patents

#4 in Boulogne-Billancourt

#91 in France

#3,266 in the World

Boulogne-Billancourt, France

Pierre Fabre Medicament

Forward Citations = 1,191

325 inventors:

Liliane Goetsch (43 out of 45 patents)

Michel Perez (24 out of 24 patents)

Bernard Vacher (22 out of 22 patents)

4. Thierry Imbert (20 out of 22 patents)

5. Jean-François Haeuw (18 out of 18 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Pierre Fabre Medicament. Retrieved from https://idiyas.com/company/pierre-fabre-medicament

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…